A Sicilian prospective observational study safety and effectiveness of Infliximab biosimilar SB2 in Inflammatory Bowel Diseases
Latest Information Update: 22 Feb 2022
At a glance
- Drugs Infliximab (Primary)
- Indications Crohn's disease; Inflammatory bowel diseases; Ulcerative colitis
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPOSIB SB2 Sicilian
Most Recent Events
- 22 Feb 2022 New trial record